Ken Griffin Amgen Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$309.38 - $337.38 $129 Million - $141 Million	-417,400 Reduced 29.15%	1,014,700 $327 Million
Q2 2024 Aug 14, 2024	BUY	$262.75 - $319.31 $74.5 Million - $90.6 Million	283,600 Added 24.69%	1,432,100 $447 Million
Q1 2024 May 15, 2024	BUY	$268.87 - $324.56 $66.2 Million - $79.9 Million	246,200 Added 27.29%	1,148,500 $327 Million
Q4 2023 Feb 14, 2024	SELL	$255.7 - $288.46 $4.63 Million - $5.22 Million	-18,100 Reduced 1.97%	902,300 $260 Million
Q3 2023 Nov 14, 2023	BUY	$218.65 - $271.46 $26.1 Million - $32.4 Million	119,500 Added 14.92%	920,400 $247 Million
Q2 2023 Aug 14, 2023	SELL	$214.27 - $253.37 $12 Million - $14.2 Million	-56,000 Reduced 6.54%	800,900 $178 Million
Q1 2023 May 15, 2023	BUY	$225.79 - $275.2 $26.4 Million - $32.1 Million	116,800 Added 15.78%	856,900 $207 Million
Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $130 Million - $166 Million	-569,700 Reduced 43.5%	740,100 $194 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $7.86 Million - $8.86 Million	-35,000 Reduced 2.6%	1,309,800 $295 Million

3,121

410M

7.56M

7.2M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $154B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.